explore -WSS

explore

author：Wikipedia 2025-09-06 04:15:00 - browse：15866

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

hotspot

WSS

New definition of a human embryo proposed amid rapid advances

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Baltimore teen accused of firing into crowd during block party mass shooting

What’s missing from the debate over nursing home staff minimums

A single Democrat is willing to weaken Medicare negotiation power

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

hotspot

explore

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

New definition of a human embryo proposed amid rapid advances

Continuity nursing helped my family in our darkest PICU moments

Liz Cheney makes 1st public comment since Trump's election interference indictments

Medicare details structure of new drug price negotiation program

Vyjuvek, a gene therapy for skin wounds, restored vision in one boy

As demand for Covid shots wanes, Moderna seeks its next success

What’s missing from the debate over nursing home staff minimums

Anesthesiologist group: stop taking Ozempic before surgery

ProMED sees offers of support, but its future remains unclear

focus

The CDC's new social media misinformation war

ActiGraph execs on goal of drug approvals with digital endpoints

New details revealed about Purdue's marketing of OxyContin

Cano Health’s bankruptcy is a warning for Medicare Advantage

What’s missing from the debate over nursing home staff minimums

Why Novartis is going to walk from its acquisition of MorphoSys

focus

knowledge

hotspot

explore